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Abstract
The invasive nature of malignant gliomas is a clinical problem rendering tumors incurable by conventional treatment
modalities such as surgery, ionizing radiation, and temozolomide. Na+/H+ exchanger regulatory factor 1 (NHERF-1) is
a multifunctional adaptor protein, recruiting cytoplasmic signaling proteins and membrane receptors/transporters
into functional complexes. This study revealed that NHERF-1 expression is increased in highly invasive cells that
reside in the rim of glioblastomamultiforme (GBM) tumors and that NHERF-1 sustains glioma migration and invasion.
Gene expression profiles were evaluated from laser capture–microdissected human GBM cells isolated from patient
tumor cores and corresponding invaded white matter regions. The role of NHERF-1 in the migration and dispersion
of GBM cell lines was examined by reducing its expression with small-interfering RNA followed by radial migration,
three-dimensional collagen dispersion, immunofluorescence, and survival assays. The in situ expression of NHERF-1
protein was restricted to glioma cells and the vascular endothelium, with minimal to no detection in adjacent normal
brain tissue. Depletion of NHERF-1 arrested migration and dispersion of glioma cell lines and caused an increase in
cell-cell cohesiveness. Glioblastoma multiforme cells with depleted NHERF-1 evidenced a marked decrease in stress
fibers, a larger cell size, and a more rounded shape with fewer cellular processes. When NHERF-1 expression was re-
duced, glioma cells became sensitized to temozolomide treatment resulting in increased apoptosis. Taken together,
these results provide the first evidence for NHERF-1 as a participant in the highly invasive phenotype of malignant
gliomas and implicate NHERF-1 as a possible therapeutic target for treatment of GBM.
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Introduction
Glioblastoma multiforme (GBM) is the most frequent form of pri-
mary brain cancer and has an average life expectancy from time of
diagnosis of only 9 months to 1 year. The highly lethal nature of this
tumor partly originates from its invasive phenotype, which affords
the tumor cells the ability to infiltrate adjacent brain tissue [1,2].
In eradicating this invasive disease, it is considered incurable using
treatment modalities presently available. As a result, identifying
and characterizing molecular mechanisms that drive the invasive be-
havior of GBM may serve as diagnostic and prognostic markers, as
well as candidate therapeutic targets.
Na+/H+ exchanger regulatory factor 1 (NHERF-1; also SLCA9A3R1)
was initially recognized as a scaffolding protein that recruits mem-
brane transporters/receptors and cytoplasmic signaling proteins into
functional complexes localized at or near the plasma membrane in
epithelial cells [3,4]. Specifically, NHERF-1 has been shown to regu-
late several G protein–coupled receptors, including receptors for
parathyroid hormone, κ-opioid, and β2-adrenergic receptors [5].
Na+/H+ exchanger regulatory factor 1 interacts with specific growth
factor receptors such as the epidermal growth factor receptor and
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platelet-derived growth factor receptor and modulates mitogenic sig-
naling by these receptor tyrosine kinases [5]. Structurally, NHERF-1
contains two tandem PDZ domains (protein-binding domains con-
served in the mammalian synaptic protein, PSD-95, Drosophila Dlg
or discs large, and the adherens junction protein, ZO-1) that can olig-
omerize with other PDZ domains to enhance scaffolding function
[6,7] as well as mediate other specific protein-protein interactions
[8]. Previous studies have shown NHERF-1 to be upregulated in
tumor tissue relative to its corresponding normal tissue in breast can-
cer [3], schwannoma [9], and hepatocellular carcinomas [10].
Whereas these studies indicate that NHERF-1 plays a role in the
progression of several cancer types, the involvement of NHERF-1 in
the pathogenesis of glioblastomas is unknown. Invasive cancer cells,
including glioblastoma, are resistant to apoptosis [11–16]. However,
decreasing the migratory capabilities of tumor cells can restore a cer-
tain level of sensitivity to cytotoxic insult [15,17]. To gain more in-
sight into the functional role of NHERF-1, changes in the levels of
this gene product in migrating primary human tumor cells were mea-
sured; NHERF-1 was depleted in GBM cell lines, then migration
and dispersion responses were assessed, cell morphology was ana-
lyzed, and the activity of the cytotoxic, alkylating agent, temozolo-
mide (TMZ), was tested.
Materials and Methods
Cell Culture Conditions and Extracellular Matrix Preparation
Human glioma cell lines SF767 [18] and T98G (American Type
Culture Collection, Manassas, VA) were maintained in minimum
essential medium (MEM; Invitrogen Corp., Carlsbad, CA) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone
Laboratories, Inc., Logan, UT) in a 37°C and 5% CO2 atmosphere
at constant humidity. Laminin from human placenta was obtained
from Invitrogen.
Clinical Samples and Histology
Human glioblastoma tumor samples were obtained from patients
who underwent primary therapeutic subtotal or total tumor resec-
tion performed under image guidance. All specimens (19 total) were
collected and submitted to the study under institutional review
board–approved protocols. No chemotherapy or radiotherapy was
performed on the patients before resection. Portions of the specimen
from the main tumor mass and the invasive rim were immediately
frozen on dry ice. Another portion was fixed in paraformaldehyde
and paraffin-embedded for histologic evaluation. Histologic diagnosis
was made by standard light microscopic evaluation of hematoxylin
and eosin (H&E)–stained sections. All tumor samples were classified
as grade 4 GBM according to the World Heath Organization [19].
Laser Capture Microdissection
Laser capture microdissection (LCM) was performed as described
previously [20–22]. Briefly, 1000 to 2000 tumor core and invasive rim
cells were dissected from 8-μm sections cut from four flash-frozen
glioblastoma (WHO grade 4) tumors. Cells in the tumor core were
identified and captured; tumor cells immediately adjacent to necrotic
areas, cortical areas, cells with small, regular nuclei, or that evidenced
features of endothelial and blood cells were avoided. White matter–
invading GBM cells were identified by means of their nuclear atypia
and heteropyknotic staining, which was consistent with that of the
cells within the tumor core. Reactive astrocytes (discriminated by their
distinct starlike morphology with eosinophilic cytoplasm and large,
acentric, round nuclei) were avoided.
RNA Isolation and Amplification
Total RNA was isolated from LCM cells using the Paradise Re-
agent System (Arcturus, Mountain View, CA), and quantified by
real-time reverse transcription–polymerase chain reaction (RT-PCR)
performed with the LightCycler (Roche Diagnostics, Indianapolis,
IN). This consisted of performing RT-PCR with Histone 3A primers
using a serial dilution of cDNA of known concentrations as standards.
The remaining RNA (approximately 10 ng) was amplified in two
rounds with the RiboAmp RNA Amplification kit (Arcturus), yielding
between 30 and 60 ng of copy RNA.
cDNA Microarray Analysis
The amount and quality of RNA preparations were evaluated on
the Agilent 2100 Bioanalyzer with RNA 6000 Nano Reagents and
Supplies (Agilent, Santa Clara, CA). The LCM analytes were hybrid-
ized to 44K Agilent Human Whole Genome oligo microarrays using
Agilent SureHyb hybridization chambers; methods for microarray hy-
bridization and washing were as described in the manufacturer’s pro-
tocol. Hybridized DNA microarrays were scanned with a resolution of
5 μm on an Agilent Scanner G2505B workstation, and TIFF images
were processed by Feature Extractor (Agilent) to measure intensity
values, which were then exported into GeneSpring software version
7 (Silicon Genetics, Santa Clara, CA). Intensity values for each probe
were divided by its control channel value in each sample; if the control
channel was below 10 then 10 was used instead. The percentiles of all
of the chips were calculated using only probes marked present. Inten-
sity value for each probe was divided by the median of its measure-
ments in all samples. Minimum Information About a Microarray
Experiment–compliant raw data for this series of experiments have
been deposited in the Gene Expression Omnibus (GEO) database
maintained by the National Center for Biotechnology Information (ac-
cession no. GSE12689).1
Tissue Microarray
Five-micrometer sections from a glioma invasion tissue microarray
(TMA) were subjected to the described staining methods using the
anti–NHERF-1 antibody sc-51684 (Santa Cruz Biotechnology, Santa
Cruz, CA). The TMA specifically contained WHO grade 4 glioma
specimens (according to standardized criteria [22]) from 10 insti-
tutes. The glioma samples were obtained from patients who under-
went primary therapeutic subtotal or total tumor resection performed
under image guidance. The glioma invasion TMA is a consequence
of an international consortium. All specimens (n = 31) were collected
and submitted to the study under institutional review board–approved
protocols. Patient information corresponding to the glioma samples on
the TMA is available through an online database.2 The formalin-fixed
paraffin-embedded tissue blocks were selected by both a neurosurgeon
and a neuropathologist from each institution as listed on the online
illumine database. In addition, each specimen block chosen met the
criteria of nonnecrotic, nonirradiated, or chemotreated glioma tissue.
Briefly, two separate face cuts were made for each of the specimens
1Reviewer access to GBM Invasion Array GEO series: http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=lbafrgcqkqomcvw&acc=GSE12689.
2Online database in Illumine may be accessed at https://illumine.5amsolutions.com/ with User-
name: reviewer, Password: glassbox2008; read-only access.
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used to construct the TMA. H&E staining was performed on the face
cuts to assist in the identification of the tumor cells. Two independent
experienced neuropathologists (Dr. Ken Aldape, MD Anderson, and
Dr. David Zagzag, New York University) reviewed the face cuts and
designated the areas of core (center of the tumor) and rim (region dis-
tal to the edge but still containing notable tumor cells). The TMA was
constructed from representative punches of tumor core and invasive
rim using an indexed manual arrayer with attached stereomicroscope
under the direction of Dr. Galen Hostetter, pathologist and Director of
the TMA core facility at Translational Genomics Research Institute.
Dr. Hostetter also reviewed and verified that the prescribed areas made
by the neuropathologists were in agreement before punches were taken
for the TMA paraffin block. Tissue microarray slides were stained by
H&E every 50 sections to confirm that tissue morphology and diag-
nosis were consistent.
Immunohistochemistry–Fluorescence Staining
The TMA slide was baked at 65°C for 1 hour, deparaffinized in
three xylene washes (2 minutes each), followed by a dehydration se-
ries of 100%, 95%, and 70% ethanol, then by rehydration in water
(20 dips each). The slide was blocked, and antigens were retrieved
using a sodium citrate–based buffer, pH 6.5, for 20 minutes (BondMax
autostainer; Vision Biosystems, Norwell, MA). The primary monoclo-
nal antibody, anti–NHERF-1 sc-51684 (Santa Cruz Biotechnology),
was diluted at 1:100 and incubated for 30 minutes. For fluorescence
staining, a 1:50 dilution of rabbit anti–glial fibrillary acidic protein
(GFAP; Cell Signaling Technology, Danvers, MA) was used to stain
the cytoplasmic portions of glial cells. A secondary antibody cocktail
containing antirabbit Alexa 555 and anti–mouse-HRP was incubated
for 30 minutes. Lastly, a tyramide signal amplification system using
Cy5 (Perkin Elmer, Waltham, MA) was used to stain the primary target
NHERF-1. The slide was coverslipped using ProLong Gold containing
DAPI (Invitrogen). For immunohistochemistry (IHC) staining, the
slide was incubated with a secondary antibody conjugated to HRP for
30 minutes followed by a diaminobenzidine (DAB) substrate. The slide
was counterstained with hematoxylin and coverslipped for imaging.
Image Acquisition and Analysis
Fluorescence-based automated and quantitative analysis (AQUA;
HistoRx technology [23,24]) measured alterations in the levels of ex-
pression of NHERF-1 within regions of interest defined by GFAP
immunoreactivity within each spot of the TMA. The AQUA score
is a numeric representation of fluorescence intensity in a user-defined
area normalized by exposure time. Multiple, monochromatic, high-
resolution (2048 × 2048 pixels) images were obtained from each
TMA spot with an Olympus BX51RFmicroscope (Olympus, Melville,
NY) [24] and analyzed with the AQUA software. For each TMA spot,
areas of tumor are distinguished from stromal elements by creating an
epithelial mask (GFAP) from the NHERF-1 protein signal, which was
visualized through the Alexa 488 fluorophore. Positivity for NHERF-1
was determined by gating the pixels, in which an intensity threshold
was set by visual inspection of TMA spots, and each pixel was recorded
as “tumor” or “nontumor” by the software on the basis of the threshold.
The DAPI image, used to designate the nuclei, was subjected to a rapid
exponential subtraction algorithm that improves signal-to-noise ratio
by subtracting the out-of-focus image from the in-focus image. After
applying the exponential subtraction algorithm, the signal intensity
of the target protein (NHERF-1), which was acquired under the Cy5
signal, was scored on a scale of 0 to 255. The AQUA score within the
subcellular compartment of the cytoplasm was calculated by dividing
the signal intensity by the area of the specified cytoplasmic compart-
ment. Further scoring by a pathologist (J.M.E.) of NHERF-1 levels
on the TMAwas performed using a system for chromophore to capture
the outcome: 1, negative to very weak; 2, moderate; 3, intense staining.
siRNA Preparation and Transfection
The siRNA oligonucleotide specific for GL2 luciferase was previ-
ously described [25]. The siRNA oligonucleotides specific for
NHERF-1 were designed, validated, and purchased from Qiagen
(Valencia, CA): NHERF-1-1 (494-514 bp; 5V-CTG CGG AAT
GGA TCA CAC TGA) and NHERF-1-2 (2631-2651 bp; 5V-AAC
TCA TTG GGT CAG CAA TTA). Transient transfection of siRNA
was carried out using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. Cells were plated in a 60-mm plate at
8.0 × 105 cells per plate in 3 ml of Dulbecco’s modified Eagle’s medium,
supplemented with 10% serum without antibiotics. Transfections
were carried out according to the manufacturer’s protocol after cells
were fully adherent (6 hours after plating). Cells were transfected with
NHERF-1 siRNA oligonucleotides or control GL2 luciferase siRNA
oligonucleotides at a concentration of 20 nM for 16 hours. No cell
toxicity was observed using this concentration of siRNA. Cells were
assayed on either day 1 or day 2 after transfection.
Western Blot Analysis
Immunoblot analysis and protein determination experiments were
preformed as previously described [26]. Briefly, monolayers of cells
were washed in phosphate-buffered saline (PBS) containing 1 mM
phenylmethylsulfonyl fluoride and then lysed in 2× sodium dodecyl
sulfate (SDI) sample buffer (0.25 M Tris-HCl, pH 6.8, 2% SDS, and
25% glycerol) containing 10 μg/ml aprotinin, 10 μg/ml leupeptin,
and 1 mM phenylmethylsulfonyl fluoride. Protein concentrations
were determined using the BCA assay procedure (Pierce, Rockford,
IL), with bovine serum albumin as reference. Fifteen micrograms of
total cellular protein was loaded per lane, separated by 10% SDS–
polyacrylamide gel electrophoresis, and then transferred to nitrocel-
lulose (Invitrogen) by electroblotting. The nitrocellulose membrane
was blocked with 5% nonfat dry milk in Tris-buffered saline (pH 8.0)
with 0.1% Tween-20 before the addition of the primary antibody and
then HRP-conjugated anti–mouse/rabbit IgG (Promega, San Luis
Obispo, CA). Bound secondary antibodies were detected using a
chemiluminescence system (NEN Life Science Products, Boston,
MA). A mouse monoclonal antibody to NHERF-1 was obtained from
Santa Cruz Biotechnology and used at a concentration of 1:1000. The
rabbit polyclonal antibody to poly(ADP-ribose)polymerase (PARP)
was obtained from Upstate Cell Signaling Solutions (Charlottesville,
VA) and used at a concentration of 1:1000. A mouse monoclonal
antibody for α-tubulin was obtained from Santa Cruz Biotechnology.
All secondary antibodies were obtained from Promega.
Radial Cell Migration Assay
Quantification of cellular migration was performed using a micro-
liter scale migration assay as described previously [26]. Briefly, 10-well
slides were coated with 10 μg/ml human laminin at 37°C for 1 hour
and washed with PBS to enhance cell attachment while promoting
migration. Approximately 2000 cells were plated onto each well of
slides using a cell sedimentation manifold (CSM, Inc., Phoenix, AZ)
to establish a confluent 1-mm-diameter monolayer. Cells transfected
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with siRNA were treated in monolayer before transferring into mani-
folds. After sedimentation and adhesion, cells were allowed to disperse
for 24 to 48 hours. Measurements of the area occupied by the cells
were taken at regular intervals for 48 hours. The average radial migra-
tion rate of five replicates was calculated as the increasing radius of the
entire cell population over time.
Three-dimensional Spheroid Dispersion Assay
Spontaneous multicellular spheroids, derived from T98G and
SF767 cells, were sandwiched between 10 μl of collagen I gel below
the spheroid and 25 μl of collagen I gel on top of the spheroid
(Vitrogen; Angiotech, Palo Alto, CA) supplemented with MEM,
2% FBS in each well of a 384-well plate (Nunc, Rochester, NY),
and overlain with 20 μl of MEM, 10% FBS. Eighteen hours after im-
plantation, dispersion assays were monitored (Axiovert 40 CFL; Zeiss,
Thornwood, NY) for up to 72 hours. Hanging drop culture [27] was
used for all subsequent spheroid production where 2 × 105 cells/ml
for T98G and SF767 lines were seeded in 20-μl droplets and cultured
in a water-filled dish for 4 days. Cells transfected with siRNA were
treated in monolayer before the formation of hanging drops.
Cell-Cell Adhesion Assay
Cells were grown to 75% confluency and treated with NHERF-1
siRNA or luciferase control overnight; the medium was changed, and
the cells were allowed to recover for 24 hours. The cells were washed
with calcium/magnesium–free PBS and detached from the culture
dishes with 4 mM EDTA in calcium/magnesium–free PBS to pre-
serve cell surface expression of cadherin subtypes. Cells were separated
to a single-cell suspension by trituration with a Pasteur pipette. After
centrifugation, the cells were suspended in a final concentration of
0.5 million cells/ml in calcium-free suspension–modified Eagle’s
medium (Invitrogen) in the absence of serum, and 106 cells were main-
tained in suspension on 1 mg/ml poly-2-hydroxyethyl methacrylate–
coated (Sigma, St. Louis, MO) 35-mm2 culture dishes to prevent cell
attachment to the substrate. Images of cells, on the substrate of at least
three fields per well, were taken after 60 minutes in culture using a
Zeiss Axiovert 40 CFL. Cell aggregates were counted based on the
number of cells per aggregate (see Results).
Immunofluoresence Microscopy
T98G and SF767 cells (n = 800) under control or siRNA
NHERF-1 conditions were cultured for 24 hours then fixed with
4% paraformaldehyde. Cells were permeabilized with 0.5% Triton
X-100 for 10 minutes, blocked with 2.5% FBS for 5 minutes, then
stained with Alexa Fluor 546–labeled phalloidin antibody at a 1:140
dilution (Invitrogen) followed by PBS washes. Omission of primary
antibody was used as a negative control. Slides were counterstained
with DAPI and coverslipped using ProLong Gold antifade reagent
with DAPI (Invitrogen). Cells were viewed using a 40× Zeiss oil im-
mersion objective on a Zeiss LSM 510 inverted confocal microscope.
Cell Viability Assay
The Alamar Blue assay (Biosource, Camarillo, CA) was used to
assess viability as described previously [28]. Briefly, 4000 cells of each
population were seeded in quadruplicate wells of 96-well plastic
plates in 200 μl of culture medium supplemented with 10% FBS.
Cells were treated with various conditions, and the assay was devel-
oped 48 hours later. Alamar Blue was then added to the cells in a
volume of 20 μl (10% of total volume) per well, and the plates were
incubated for 6 hours at 37°C. The plates were read on a fluorescence
plate reader (excitation, 560 nm; emission, 600 nm). Averages of
the fluorescence values were calculated and normalized to controls
without TMZ (Sigma; IC50 of 250 μM for T98G and 125 μM
for SF767).
Results
NHERF-1 Expression Is Increased in Invasive Glioma
Cells In Vivo
We examined whether increased expression of NHERF-1 coincided
with the migratory behavior of invasive glioma cells in vivo. Two paired
glioma subpopulations, from the tumor core or the invasive rim, were
isolated from 19 specimens. Using gene expression profiling, followed
by fold change analysis, we selected genes that were differentially regu-
lated in the tumor core and the rim. One of the candidate genes iden-
tified to be overexpressed in the rim of more than 50% of the tumors
was NHERF-1. In 10 of 19 glioblastoma core and rim biopsies, sam-
ples of cells invading at the rim showed 1.5- to nearly 6-fold induction
of NHERF-1 compared with cells isolated from the core (Figure 1).
Because of the heterogeneity of glioblastoma, it is not surprising that
only a little more than 50% of the population exhibited an overexpres-
sion of NHERF-1 in the invasive rims of the tumors. Quantitative
real-time polymerase chain reaction (qRT-PCR) validated the over-
expression of NHERF-1 in 9 of the 10 GBM cases and validated the
underexpression of NHERF-1 in 7 of the 9 glioma samples (data not
shown). These findings substantiate that up-regulation ofNHERF-1 ac-
companies migration of tumor cells at the rim of GBM tumor samples.
Immunohistochemical Validation of NHERF-1 Protein
Expression in a Brain Tumor TMA
The protein expression of NHERF-1 from a series of primary hu-
man glioblastoma specimens (independent sample set from the 19
specimens described previously) assembled on a TMA consisting of
38 tumor cases containing core and rim was examined by immuno-
fluorescence staining. AQUA scores [23] of NHERF-1 within GFAP
regions of interest were derived for matched samples. Greater levels
of NHERF-1 expression (AQUA score > 1) were observed in the in-
vasive rim compared with the core in 31 of 38 cases (Figure 2, A
and B). Because AQUA is a relatively recent technology for quanti-
Figure 1. Na+/H+ exchanger regulatory factor 1 is overexpressed
in invasive GBM cells. From 19 independent GBM specimens,
1000 to 2000 stationary (core) and invasive (rim) cells were har-
vested by LCM for microarray analysis. Relative NHERF-1 mRNA
signal intensity was expressed as a ratio of rim to core.
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fying immunofluorescence in tissue, data from Figure 2, A and B,
were confirmed by DAB-IHC staining and manual visual scoring
of NHERF-1 using sections from the same TMA. Of the 31 evalu-
able GBM cores, 5 were negative to weakly positive (16%, score = 1),
14 were moderately positive (42.4%, score = 2), and 12 were intensely
positive (38%, score = 3). Of the 31 evaluable GBM rims, 1 was nega-
tive to weakly positive (3%, score = 1), 6 were moderately positive
(19%, score = 2), and 24 were intensely positive (77%, score = 3;
Figure 2. Quantitative analysis of NHERF-1 expression in 38 human glioma tumors. (A) AQUA scores of NHERF-1 protein levels were
measured in matched sets of rim:core for each tumor; ratio of AQUA scores for each specimen are plotted, ranked from low to high.
Samples with an AQUA score fold difference above “1” indicates significant up-regulation (indicated by horizontal bar). (B) Paraffin sec-
tion of tumor core from specimen no. A13 on glioma TMA immunofluorescently stained with a monoclonal antibody against NHERF-1
and analyzed by a HistoRx imaging system. Red, NHERF-1 staining; green, GFAP for glial fiber staining; blue, DAPI nuclear staining.
Tumor core original magnifications, ×10 (a) and ×20 (b). (C) Paraffin sections of tumor-free nonneoplastic brain (a, b), glioma core (c, d),
and invasive rim (e, f) from TMA immunostained against NHERF-1. Original magnifications, ×10 (a, c, e) and ×20 (b, d, f). Arrows in-
dicate representative NHERF-1 positive staining. (D) The DAB-IHC scoring of NHERF-1 expression of the TMA.
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Figure 2D). The immunoreactivity of NHERF-1 was observed in
both glioblastoma tumor cores (Figure 2C : c and d ) and invading
cells (Figure 2C : e and f ). The highest amount of NHERF-1 protein
expression was found in GBM cells at the invasive rims of these tumors.
There are 3 (9.3% of matched samples) of the 31 cases where NHERF-
1 expression is elevated in the cores compared with that in the rims
(score of 3 in cores and 2 in rims). These contradicting results could
be attributed to the heterogeneity of the disease. Examination of
Figure 3. Na+/H+ exchanger regulatory factor 1 inhibits migration and dispersion in vitro. Reduction of NHERF-1 using siRNA decreases
glioma migration/dispersion. (A) Western blot analysis (α-tubulin used as a loading control) to confirm reduction of NHERF-1 in the
glioma cell lines T98G and (B) SF767 transfected with two NHERF-1–specific siRNA. Untransfected cells and cells transfected with a
control siRNA (luciferase) are shown for comparison. Treatment with two separate NHERF-1 siRNA decreased migration of (C) T98G
(luciferase: 7.7 ± 0.53 μm/h, NHERF-1-1: 2.2 ± 0.94 μm/h, NHERF-1-2: 0.82 ± 0.53 μm/h) and (D) SF767 cells in a radial migration assay
when compared with untreated or luciferase-transfected cells (luciferase: 11.6 ± 0.46 μm/h, NHERF-1-1: 3.3 ± 0.65 μm/h, NHERF-1-2:
5.2 ± 1.4 μm/h). Values shown are the average of 5 ± SEM and representative of three independent experiments. For T98G cells: *P <
.01, comparing luciferase-treated cells to NHERF-1-1–treated cells; **P < .01, comparing luciferase-treated cells to NHERF-1-2–treated
cells. For SF767 cells: *P < .001, comparing luciferase-treated cells to NHERF-1-1–treated cells; **P < .001, comparing luciferase-
treated cells to NHERF-1-2–treated cells; 2-tailed Student’s t-test. (E) Dispersion of T98G cells from multicellular spheroid in 1% collagen
is inhibited when NHERF-1 is depleted. Upper left panel indicates luciferase-transfected spheroid at 0 hour, upper right panel after
72 hours. Lower left panel indicates NHERF-1 siRNA-transfected (combination of the two sequences) spheroid at 0 hour, lower right
panel after 72 hours. (F) Depletion of NHERF-1 causes SF767 cells to form large spheroids in 1% collagen culture. Upper left panel in-
dicates luciferase-transfected spheroid at 0 hour, upper right panel after 72 hours. Lower left panel indicates NHERF-1 siRNA-transfected
(combination of the two sequences) spheroid at 0 hour, lower right panel after 72 hours. Images shown are representative of three inde-
pendent experiments.
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NHERF-1 levels in control nonneoplastic autopsy brain specimens
(Figure 2C : a and b) showed negative to very weak staining of
NHERF-1, which was present in some reactive astrocytes, as confirmed
by a pathologist (J.M.E.).
Depletion of NHERF-1 in Glioma Cells Inhibits Migration
and Dispersion and Increases Cell-Cell Adhesion In Vitro
To examine the functional roles of NHERF-1, two independent
sequences of siRNA designed specifically to inhibit NHERF-1 were
introduced into T98G and SF767 glioma cells. Western blots were
performed to assess the level of NHERF-1 in both cell lines trans-
fected with either a luciferase control or two NHERF-1 siRNA. Fig-
ure 3, A and B, confirms the decrease of NHERF-1 protein levels
in NHERF-1 siRNA-transfected T98G and SF767 cells relative to un-
transfected and luciferase controls. Furthermore, NHERF-1 mRNA
was reduced by approximately 60% to 90% by both NHERF-1-1
and NHERF-1-2 siRNA as a confirmation by qRT-PCR (data not
shown). Monolayer radial migration assays revealed that reduction of
NHERF-1 in T98G and SF767 glioma cells significantly decreased in
migration rates relative to mock-transfected cells (Figure 3, C and D).
In addition, cell spheroids that propagated three-dimensionally in
collagen I gel indicate that inhibition of NHERF-1 by two indepen-
dent NHERF-1 siRNA causes an evident decrease or total lack of cell
dispersion of T98G glioma cells relative to mock-transfected cells
(Figure 3E ). Moreover, depletion of NHERF-1 expression in
SF767 cells resulted in tight and robust spheroid formations in con-
trast to untreated cells that are typically incapable of spheroid forma-
tion and dispersion in collagen I gel (Figure 3F ). In addition, when
NHERF-1 levels are decreased, T98G and SF767 glioma cells
showed a significant increase in cell-cell adhesion, through aggregate
formation, compared with control cells treated with luciferase siRNA
(Figure 4). Moreover, when NHERF-1 was depleted, T98G and
SF767 glioma cells showed a significant increase in cell-cell matrix
adhesion compared with control cells treated with luciferase plated
on either bovine serum albumin or laminin (data not shown). These
Figure 4. Depletion of NHERF-1 results in increased glioma cell aggregation. (A) Photomicrographs (phase contrast) of T98G and SF767
cells treated with NHERF-1 siRNA (combination of the two sequences) – or luciferase siRNA (control). Scale bar, 20 μm. (B) T98G (cell
aggregates: [5-10 cell size] luciferase, 28.67 ± 4.16; NHERF-1 siRNA, 11.00 ± 1.00; [50-100 cell size] luciferase, 14.33 ± 5.51; NHERF-1
siRNA, 6.33 ± 1.15; [500+ cell size] luciferase, 3.33 ± 0.58; NHERF-1 siRNA, 35.67 ± 9.61) and (C) SF767 cell suspensions were scored
visually for aggregated cells after 60 minutes in culture (cell aggregates: [5-10 cell size] luciferase, 32.00 ± 2.00; NHERF-1 siRNA, 15.33 ±
4.04; [10-50 cell size] luciferase, 12.33 ± 5.51; NHERF-1 siRNA, 21.33 ± 3.21; [100+ cell size] luciferase, 6.67 ± 2.08; NHERF-1 siRNA,
38.33 ± 0.58). Bars, the average number of cell aggregates after NHERF-1 siRNA. Values represent the mean and SD from three ran-
domly selected fields. *P < .03, **P < .01, when comparing NHERF-1 siRNA-treated cell aggregates with corresponding luciferase-
transfected control cell aggregates (2-tailed Student’s t-test).
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findings suggest that when NHERF-1 is downregulated, dispersion
from a multicellular spheroid is compromised, and cells undergo a
phenotypic switch causing an increase in cell-cell cohesion, likely
due to the expression of one or more cell adhesion molecules.
NHERF-1 Reduction Causes a Morphologic Change in
Glioblastoma Cells Accompanied by Reorganization
of the Actin Cytoskeleton
The resulting effects on motility and dispersion described above
led us to examine the influence of NHERF-1 on T98G and SF767
cell morphology and cytoskeleton organization. Previous studies in a
breast cancer model have shown that tumor cells that overexpressed
NHERF-1 induced leading-edge pseudopodia and localized
NHERF-1 to the pseudopodial tips, suggesting a role for NHERF-1
in tumor migration [29]. We therefore investigated the effects of
NHERF-1 on actin using Alexa Fluor 546–labeled phalloidin, which
binds to F-actin, and counterstained the nuclei with DAPI. The cells
were transfected with NHERF-1 siRNA, or with the control siRNA
specific for luciferase, for 24 hours under the same conditions as those
used in the radial migration assay, stained, and then imaged. Fluores-
cent images of the stained cells (red, actin; blue, nucleus) are shown
in Figure 5. In the control cells (left panels), F-actin was organized
in stress fibers and morphologically showed small cell bodies with
long extensions indicative of cell migration. In the NHERF-1 siRNA-
treated T98G and SF767 cells, most of the F-actin was diffuse, and
the cells exhibited a rounder and much larger morphology (right
panels). The NHERF-1 knockdown resulted in a decrease in stress
fibers and focal adhesions, suggesting that their assembly had beenweak-
ened, which could contribute to the cells’ decreased migration and in-
creased cohesion.
NHERF-1 siRNA Sensitizes Glioma Cells to TMZ
There has been prior evidence indicating that apoptosis is sup-
pressed when cells convey a migratory phenotype [30–33]. Because
we have shown NHERF-1 to be a regulator of cell migration and ad-
hesion, we evaluated whether depletion of NHERF-1 affected glioma
cell sensitivity to TMZ treatment. Both T98G and SF767 cells were
significantly more sensitive to cell death when NHERF-1 was depleted
followed by 48 hours of treatment with 250 or 125 μM TMZ, re-
spectively, compared with the luciferase controls treated with TMZ
(Figure 6, A and B).
Furthermore, validation of increased apoptosis by TMZ after the
inhibition of NHERF-1 was confirmed by Western blot analysis of
PARP cleavage after 24 hours of TMZ treatment. T98G and SF767
glioma cell lines manifest minimal levels, if any, of PARP cleavage
when untreated, when treated with luciferase, or when in the pres-
ence of NHERF-1 siRNA alone. However, when both cell lines were
first introduced with NHERF-1 siRNA, then treated with TMZ for
24 hours, there was a pronounced increase in the levels of PARP
cleavage compared with cells treated with TMZ alone or in combi-
nation with luciferase siRNA (Figure 6C ). These results indicate that
when NHERF-1 is inhibited in glioma cells, they are sensitized to
TMZ treatment evidenced by an increase in apoptotic cell death.
Discussion
We report that increased levels of NHERF-1 protein and mRNA
expression associate with the invasive behavior of malignant glioma
cells in vivo. In addition, immunohistochemical validation using a
brain tumor TMA portrays the highest level of NHERF-1 protein
expression in GBM cells at the invading rims of the tumors rather
Figure 5. Na+/H+ exchanger regulatory factor 1 inhibition causes morphological changes in glioma cells. T98G and SF767 cells with or
without NHERF-1 siRNA treatment were seeded at a density of 1 × 104 per well on laminin-coated 10-well slides. After 24 hours, cells
were fixed and stained with Alexa Fluor 546–labeled phalloidin (red fluorescence) and counterstained with DAPI (blue fluorescence).
Confocal fluorescence images were taken (objective, 40×; scale bar, 10 μm).
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than at the tumor cores. Examination of NHERF-1 levels in non-
neoplastic autopsy brain sections showed negative to very weak stain-
ing of NHERF-1, which occurred mainly in reactive astrocytes.
Knockdown of NHERF-1 elicits antimigratory and antidispersive
phenotypes in glioma cells as well as an increase in cell-cell adhesion.
Moreover, a decrease in stress fibers and a morphological change were
observed on NHERF-1 depletion in GBM cell lines. When NHERF-1
is inhibited, glioma cells become sensitized to cytotoxic effects of
TMZ and undergo apoptotic cell death. These results suggest that
NHERF-1 is a candidate therapeutic target of invasive glioma.
Na+/H+ exchanger regulatory factor 1 has an established function
as a scaffolding protein that recruits membrane receptors/transporters
and cytoplasmic signaling proteins into functional complexes local-
ized at or near the plasma membrane [4]. In addition, NHERF-1
is overexpressed in several tumor types, including schwannoma [9]
and hepatocellular carcinomas [10], and in breast cancer [3]. In the
current study, NHERF-1 is reported to be differentially upregulated
in migrating and invading human glioma cells, above elevated levels
in the tumor core.
In a recent study, it was reported that NHERF-1 expression is
found in varying amounts within regions of the normal rodent brain.
Notably, neuronal elements (i.e., neuronal cell bodies visible in the
granular layer of the dentate gyrus and the pyramidal cell bodies in the
stratum pyramidale in the CA1 region of the hippocampus) did not
contain NHERF-1; however, astrocytes surrounding such neurons
were densely labeled [34]. In our study, NHERF-1 is strongly expressed
in GBM cells located in the invading rim of human glioblastoma
samples relative to tumor core and suggests that NHERF-1 may be a
driver or contributor to glioblastoma invasion. Our laser-captured
microarray data set is unique in its ability to decipher the expression
of core and invasive rims of GBM tumors. We also accessed the
REMBRANDT public expression data set, representative of brain
tumor cores (http://caintegrator-info.nci.nih.gov/rembrandt). The
REMBRANDT database expression of NHERF-1 was unchanged
across tumor grade for the core biopsies available. Furthermore, in a
recent breast cancer study, overexpression of NHERF-1 in MDA-
MB-435 cells promoted a hypoxic or serum-deprived tumor microen-
vironment and induced leading-edge pseudopodia and corresponding
redistribution of NHERF-1 to the pseudopodia tip [29]. Moreover,
Cardone et al. [29] determined that escaping MDA-MB-435 cells from
tumor lobules contained in three-dimensional Matrigel culture revealed
NHERF-1 disproportionately localized to the pseudopodial tip of the
escaping and invading tumor cells, suggesting a role for NHERF-1 in
tumor cell invasion. These studies demonstrate that NHERF-1 is in-
volved in cytoskeletal reorganization and motility. In support of these
results, we find that glioblastoma cells lose their ability to migrate on
Figure 6. Effect of NHERF-1 siRNA on vulnerability of T98G and SF767 cells to TMZ. (A) T98G and (B) SF767 cells were treated for
48 hours with NHERF-1 siRNA along with either 250 or 125 μM TMZ treatment, respectively. Bars, percentage cell survival normalized
to the controls not containing TMZ. Values represent mean and SD from three independent experiments (T98G [% survival ± % SD]:
NHERF-1-1 + TMZ: 23.17 ± 0.967, NHERF-1-2 + TMZ: 23.38 ± 0.948) (SF767 [% survival ± % SD]: NHERF-1-1 + TMZ: 32.65 ± 1.08,
NHERF-1-2 + TMZ: 36.77 ± 0.235). For T98G cells: *P < .01, comparing luciferase-treated cells to NHERF-1-1–treated cells; **P < .01,
comparing luciferase-treated cells to NHERF-1-2–treated cells. For SF767 cells: *P < .001, comparing luciferase-transfected cells treated
with TMZ to NHERF-1-1–transfected cells treated with TMZ; **P< .001 comparing luciferase-transfected cells treated with TMZ to NHERF-
1-2–transfected cells treated with TMZ (2-tailed Student’s t-test). Data are representative of two independent experiments, each run
with triplicate samples. (C) Western blot analysis to determine PARP cleavage. T98G and SF767 glioma cells were treated with nothing,
luciferase, NHERF-1-1, or NHERF-1-2 siRNA with or without TMZ. After 24 hours, whole-cell lysates were prepared and immunoblotted for
whole and cleaved PARP. Ponceau staining was used as a loading control. Data are representative of two independent experiments.
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laminin or to invade in a collagen-based environment when NHERF-1
is depleted.
Our experiments also show that SF767 cells, which typically are
unable to form spontaneous spheroids, generate self-aggregating multi-
cellular assemblies after depleting NHERF-1 by siRNA. It also seems
that when NHERF-1 levels are decreased in T98G cells, the spheroids
adopt very tight and well-defined borders. On the basis of these obser-
vations, we evaluated the propensity of single-cell suspensions of T98G
and SF767 cells to develop cell-cell cohesion. Cell-cell cohesion assays
clearly showed that NHERF-1 knockdown elicited stronger cell-cell
aggregation when compared with luciferase-transfected control cells.
A quantitative measurement of cell-cell adhesion after 60 minutes in
culture, scored as aggregates as clumps of cells, revealed that glioma
cells with decreased NHERF-1 expression had significantly higher
numbers of aggregates of a larger size, compared with that in luciferase-
transfected control cells. These increases in aggregation were consequent
to depletion of NHERF-1, suggesting that an adhesion molecule(s)
is likely involved in NHERF-1–related cell-cell adhesion. In addition,
the presence of NHERF-1 induces a promotility phenotype resulting
in actin cytoskeletal rearrangements that decrease the adhesive properties
of the cells. Our data determined that when NHERF-1 is present in
glioma cells, there are prevalent stress fibers observed within elongated
motile cell bodies. However, when NHERF-1 is diminished, there is a
visible decrease in stress fibers. A more rounded cell is also observed along
with what appeared to be focal adhesion complexes in many of the cells.
These data suggest that NHERF-1 plays a major role in tumor cell mi-
gration and dispersion, and when inhibited, glioma cells cease to migrate
and possibly increase the expression of cell adhesion molecules. On the
basis of these phenotypic data, we speculate that NHERF-1 is involved in
integrin signaling pathways leading to motility and stress fiber induction
in glioma cells. Studies are underway to investigate the mechanism of
regulation of adhesion- and migration-based molecules by changes in
NHERF-1 expression, particularly the role of integrin-mediated signal-
ing processes.
A major characteristic of glioblastoma is the propensity to invade
and become resistant to chemotherapeutic agents [15,26,35–39].
Temozolomide is an oral alkylating agent that readily crosses the
blood–brain barrier, and it has been used for the treatment of brain
cancer since 1999. It induces apoptosis in neoplastic cells by inter-
fering with DNA replication [40]. However, a main cause of treat-
ment failure, with TMZ treatment [41], is the ability of tumor cells
to acquire resistance to apoptosis, which is necessary for tumor de-
velopment and progression [37,42]. The absence of apoptosis resis-
tance would otherwise induce tumor cell death when deprived of the
support from neighboring cancer cells [15,37,42]. In this study, cell
migration and dispersion are inhibited and an increased sensitization
of glioblastoma cells to TMZ treatment is observed when NHERF-1
expression is depleted. Specifically, NHERF-1 down-regulation in
conjunction with TMZ treatment showed an increase in apoptosis
versus TMZ treatment alone. A possible molecular link between
migration arrest due to NHERF-1 inhibition and enhanced TMZ-
induced apoptosis is currently under investigation.
In summary, our current findings indicate an important role of
NHERF-1 in the regulation of glioma cell migration and dispersion.
Significantly, these data provide the first evidence that NHERF-1 is
upregulated in migrating GBM cells in vitro and in vivo, and when
silenced, tumor cells exhibit little to no migratory or dispersion ac-
tivity leading to an increased susceptibility and vulnerability to che-
motherapy. Specifically, when NHERF-1 is inhibited, glioma cells
become sensitized to TMZ treatment. Further investigation of down-
stream signaling mechanisms of NHERF-1 related to adhesion mole-
cules needs to be conducted to determine its role in glioma invasion.
It is necessary to understand the biologic functions of NHERF-1 to
allow innovative therapeutic interventions to be developed with the
goal of targeting migratory and invasive glioma cells.
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Supplemental Data
Supplemental Method: qRT-PCR
Real-time quantitative PCR was performed using a Light-Cycler
(Roche Diagnostics) with SYBR green fluorescence signal detection.
Briefly, total RNA was isolated from human brain tumor tissues using
the Paradise Reagent System (Arcturus). cDNA was synthesized from
1 μg of DNase I–treated total RNA in a 20-μl reaction volume using
the Retroscript kit (Ambion Inc., Austin, TX) for 60 minutes at 42°C.
Quantitative real-time polymerase chain reaction was performed on
2.5 μl of the cDNA diluted 1:5 from final Retroscript reaction using
the following primers: NHERF-1, sense 5′-CCT TCA CCA ATG
GGG AGA TA-3′ and antisense 5′-GGT CGG AGG AGG AGG
TAG AC-3′ (amplicon size, 207 bp); histone 3A, sense 5′-CCA CTG
AAC TTC TGATTC GC-3′ and antisense 5′-GCG TGC TAG CTG
GAT GTC TT-3′ (amplicon size, 215 bp; Operon, Huntsville, AL).
The qRT-PCR data were analyzed with the LightCycler analysis soft-
ware to calculate crossing point values. The difference in the cycle
number was normalized to the housekeeping gene histone 3A (H )
and then used to calculate the fold difference in copy number according
to the formula: F = 2−(HsiRNA − HsiRNA)(HNT − HNT), where F is fold
difference in NHERF-1 expression, H is histone 3A, N is NHERF-1
(gene of interest), siRNA is siRNA-treated cells, and NT is cells given
no treatment (Figure W1).
Figure W1. A total of 1000 to 2000 stationary (core) and invasive
(rim) cells collected on frozen slides from 19 independent GBM
patients were harvested by LCM for microarray analysis and quanti-
tative RT-PCR. Amplified cDNA, 2.5 μl, from samples collected in
Figure 1Awere used to validate NHERF-1 gene expression profiling.
